May 13, 2024 4:16pm EDT Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
Apr 10, 2024 7:03am EDT Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Mar 28, 2024 4:15pm EDT Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
Mar 25, 2024 7:03am EDT Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
Mar 13, 2024 7:03am EDT Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
Mar 07, 2024 4:12pm EST Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
Mar 04, 2024 7:03am EST Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
Feb 14, 2024 7:03am EST Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
Jan 29, 2024 7:03am EST Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
